PT Ikapharmindo Putramas Tbk (IDX:IKPM)
Indonesia · Delayed Price · Currency is IDR 196.00
0.00 (0.00%)
Last updated: Aug 7, 2025
Sage Therapeutics Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 392,289 | 412,069 | 441,137 | 398,735 | 380,917 | 715,801 | |
Revenue Growth (YoY) | -7.56% | -6.59% | 10.63% | 4.68% | -46.78% | - |
Cost of Revenue | 220,050 | 226,541 | 252,169 | 217,946 | 203,645 | 453,102 |
Gross Profit | 172,240 | 185,528 | 188,968 | 180,788 | 177,272 | 262,700 |
Selling, General & Admin | 166,034 | 165,389 | 156,810 | 147,732 | 152,267 | 231,485 |
Other Operating Expenses | 2,702 | 2,625 | 378.47 | -169.92 | - | -451.49 |
Operating Expenses | 168,736 | 168,014 | 157,188 | 147,562 | 152,267 | 231,033 |
Operating Income | 3,503 | 17,514 | 31,780 | 33,226 | 25,005 | 31,666 |
Interest Expense | -11,935 | -10,778 | -11,286 | -11,611 | -12,349 | -22,853 |
Interest & Investment Income | 17.78 | 28.87 | 28.42 | 330.25 | 31.46 | 26.52 |
Currency Exchange Gain (Loss) | 684.62 | 684.62 | -369.61 | 920.19 | 460.5 | 191.9 |
EBT Excluding Unusual Items | -7,729 | 7,449 | 20,153 | 22,866 | 13,148 | 9,032 |
Gain (Loss) on Sale of Investments | - | - | - | -115.2 | -2,431 | - |
Gain (Loss) on Sale of Assets | 585.28 | 585.28 | 631.68 | -30.16 | 1,395 | 1,741 |
Pretax Income | -7,144 | 8,035 | 20,785 | 22,721 | 12,111 | 10,773 |
Income Tax Expense | 1,290 | 3,020 | 5,447 | 6,143 | 3,986 | 6,145 |
Net Income | -8,433 | 5,015 | 15,338 | 16,578 | 8,125 | 4,628 |
Net Income to Common | -8,433 | 5,015 | 15,338 | 16,578 | 8,125 | 4,628 |
Net Income Growth | - | -67.30% | -7.48% | 104.02% | 75.56% | - |
Shares Outstanding (Basic) | 1,685 | 1,685 | 898 | 1,000 | 1,000 | 1,000 |
Shares Outstanding (Diluted) | 1,685 | 1,685 | 898 | 1,000 | 1,000 | 1,000 |
Shares Change (YoY) | 58.19% | 87.63% | -10.21% | - | - | - |
EPS (Basic) | -5.00 | 2.98 | 17.08 | 16.58 | 8.13 | 4.63 |
EPS (Diluted) | -5.00 | 2.98 | 17.08 | 16.58 | 8.13 | 4.63 |
EPS Growth | - | -82.57% | 3.05% | 104.02% | 75.56% | - |
Free Cash Flow | -27,967 | -37,562 | -23,743 | -7,047 | 76,396 | 7,159 |
Free Cash Flow Per Share | -16.59 | -22.30 | -26.45 | -7.05 | 76.40 | 7.16 |
Dividend Per Share | - | - | 2.250 | - | - | - |
Gross Margin | 43.91% | 45.02% | 42.84% | 45.34% | 46.54% | 36.70% |
Operating Margin | 0.89% | 4.25% | 7.20% | 8.33% | 6.56% | 4.42% |
Profit Margin | -2.15% | 1.22% | 3.48% | 4.16% | 2.13% | 0.65% |
Free Cash Flow Margin | -7.13% | -9.12% | -5.38% | -1.77% | 20.06% | 1.00% |
EBITDA | 11,146 | 25,345 | 41,844 | 43,116 | 36,767 | 44,943 |
EBITDA Margin | 2.84% | 6.15% | 9.49% | 10.81% | 9.65% | 6.28% |
D&A For EBITDA | 7,642 | 7,831 | 10,064 | 9,889 | 11,763 | 13,277 |
EBIT | 3,503 | 17,514 | 31,780 | 33,226 | 25,005 | 31,666 |
EBIT Margin | 0.89% | 4.25% | 7.20% | 8.33% | 6.56% | 4.42% |
Effective Tax Rate | - | 37.58% | 26.21% | 27.04% | 32.91% | 57.04% |
Advertising Expenses | - | 62,070 | 55,739 | 50,454 | 81,155 | 97,424 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.